最近の記事
- 2025/06/17
- 患者がん移植ゼブラフィッシュモデル(PDXZ)の臨床展開
- 2025/06/02
- ポドサイトパチー創薬スクリーニング
- 2025/04/23
- ポドサイトパチー治療薬スクリーニング
- 2025/04/10
- 患者がん移植ゼブラフィッシュモデル(PDXZ)の展開
- 2025/02/05
- ゼブラフィッシュによるoncocardionephrologyの展開
- 2025/01/01
- ゼブラフィッシュ創薬のグローバル展開
- 2024/10/28
- 医療ビッグデータ時代における次世代AIDXゼブラフィッシュ創薬研究開発
- 2024/09/02
- ゼブラフィッシュによるOncocardiologyとOnconephrology
| 2025/10/07 |
|
AI-Driven Precision Patient-Derived Cancer Xenograft Zebrafish System Protocol
Since 2024, the clinical implementation of Patient-Derived Xenograft Zebrafish systems (PDXZ) has accelerated. For example, a validation study involving 55 colorectal cancer patients demonstrated that the PDXZ system predicted patient treatment response with 91% accuracy (Nature Communications 2024 Jun 5;15:4771). Furthermore, the XenoZ clinical trial (NCT03668418), led by Portugal's Champalimaud Foundation, is the world's first randomized trial involving 120 pancreatic and gastrointestinal cancer patients, with patient enrollment beginning in January 2025. Therefore, anticipating rapid progress toward future clinical implementation, we attempted to maximize accuracy by minimizing non-clinical variability factors in this PDXZ protocol, focusing on the following three points for personalized medical decision-making and drug discovery screening decisions: We report the development of: 1) a fully individualized system to support the complete automation of PDXZ expected globally by 2030, 2) AI-based quality control for zebrafish hosts, and 3) AI-based quality control for patient tumor transplantation.
関連リンク
関連ファイル
